"Mesalamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
| Descriptor ID |
D019804
|
| MeSH Number(s) |
D02.241.223.100.050.300.500 D02.241.223.100.300.595.100.540 D02.241.511.390.595.100.540 D02.455.426.559.389.127.020.452.750 D02.455.426.559.389.127.281.595.100.540 D02.455.426.559.389.657.410.595.100.540
|
| Concept/Terms |
Mesalamine- Mesalamine
- Mesalazine
- m-Aminosalicylic Acid
- m Aminosalicylic Acid
- 5-Aminosalicylic Acid
- 5 Aminosalicylic Acid
- meta-Aminosalicylic Acid
- meta Aminosalicylic Acid
|
Below are MeSH descriptors whose meaning is more general than "Mesalamine".
Below are MeSH descriptors whose meaning is more specific than "Mesalamine".
This graph shows the total number of publications written about "Mesalamine" by people in this website by year, and whether "Mesalamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 3 | 3 |
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 3 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 3 | 4 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 5 | 1 | 6 |
| 2004 | 4 | 2 | 6 |
| 2005 | 6 | 1 | 7 |
| 2006 | 3 | 3 | 6 |
| 2007 | 3 | 0 | 3 |
| 2008 | 5 | 1 | 6 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 4 | 0 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mesalamine" by people in Profiles.
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
-
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Aliment Pharmacol Ther. 2020 12; 52(11-12):1676-1682.
-
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281.
-
Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Dig Dis Sci. 2021 02; 66(2):577-586.
-
Too Soon to Discard 5-ASAs? Am J Gastroenterol. 2019 03; 114(3):534-535.
-
ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
-
Lymphocytic colitis: pathologic predictors of response to therapy. Hum Pathol. 2018 08; 78:1-7.
-
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
-
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6.
-
Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.